Scilex Holding (SCLX) Cash from Financing Activities (2020 - 2026)

Scilex Holding (SCLX) posted quarterly Cash from Financing Activities of $9.1 million for Q1 2026, up 396.5% year-over-year from $1.8 million in Q1 2025, and down 47.81% on a QoQ basis from $17.5 million in Q4 2025.

Scilex Holding (SCLX) Cash from Financing Activities (2020 - 2026) Analysis & Trends

Scilex Holding (SCLX) has reported Cash from Financing Activities for 7 consecutive years, with $9.1 million the latest figure, recorded in Q1 2026.

  • In Q1 2026, Cash from Financing Activities rose 396.5% year-over-year to $9.1 million; the TTM figure through Mar 2026 stood at $6.8 million (up 167.54% YoY), while the FY2025 annual figure was -$5.5 million, up 69.88% from the prior year.
  • Cash from Financing Activities came in at $9.1 million for Q1 2026 at Scilex Holding, down from $17.5 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $43.5 million in Q2 2023, with the low at -$38.9 million in Q3 2023.
  • Average Cash from Financing Activities over 5 years is $1.8 million, with a median of -$3.1 million recorded in 2025.
  • The largest YoY upside for Cash from Financing Activities was 1849.77% in 2023 against a maximum downside of 466.26% in 2023.
  • Year by year, Cash from Financing Activities stood at $426000.0 in 2022, then jumped by 1849.77% to $8.3 million in 2023, then sank by 186.48% to -$7.2 million in 2024, then soared by 343.91% to $17.5 million in 2025, then plunged by 47.81% to $9.1 million in 2026.
  • According to Business Quant data, Cash from Financing Activities over the past three periods registered $9.1 million, $17.5 million, and -$11.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn -3.47 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn 530.00 Mn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn 919.00 Mn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn 267.00 Mn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn -2.98 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn 1.44 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn -4.24 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn -2.86 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn - -
10 Scilex Holding 54.30 Mn -95.62 Mn 4.15 Mn 9.14 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 9.14 Mn
Mar 31, 2026 9.14 Mn
Dec 31, 2025 17.52 Mn
Dec 31, 2025 17.52 Mn
Sep 30, 2025 -11.30 Mn
Sep 30, 2025 -11.30 Mn
Jun 30, 2025 -8.60 Mn
Jun 30, 2025 -8.60 Mn
Mar 31, 2025 -3.08 Mn
Mar 31, 2025 -3.08 Mn
Dec 31, 2024 -7.18 Mn
Dec 31, 2024 -7.18 Mn
Sep 30, 2024 -4.48 Mn
Sep 30, 2024 -4.48 Mn
Jun 30, 2024 4.73 Mn
Jun 30, 2024 4.73 Mn
Mar 31, 2024 -11.20 Mn
Mar 31, 2024 -11.20 Mn
Dec 31, 2023 8.31 Mn
Dec 31, 2023 8.31 Mn